Led · Series A · May 2026

BranchLab has built a privacy-first, AI-native platform that replaces fragmented, offline commercialization workflows for pharmaceutical companies by putting audience identification, activation, and optimization into near real-time use. Its transformer-based architecture allows models to be trained within customer-controlled environments while deploying only non-sensitive demographic and media-side signals. BranchLab says leading pharmaceutical companies use the platform and that it has driven an average increase of nearly 70% in marketing efficacy across therapeutic areas. The company is based in Boulder, Colo., and has raised a total of $35 million after closing a $26 million Series A. BranchLab plans to use the new funding to expand enterprise deployments, deepen integrations across the healthcare and media ecosystem, and further develop its unified AI commercialization platform.

Participated · Series A · Apr 2026

Latent builds a Clinical Reasoning Engine that reasons over patient data, interprets drug criteria, extracts key evidence, and orchestrates workflows across EHRs, payers, pharmacies, and patients to close the gap between diagnosis and treatment. The company began with prior authorization workflows and has expanded the engine across multiple processes where clinical knowledge must be translated into action. Latent serves more than 2 million patients annually and partners with over 45 health systems, including customers that represent 50% of the top 20 U.S. health systems. The company reports reducing denials by over 30% and enabling clinicians to serve twice as many patients. Latent plans to broaden its health system footprint, deepen platform integrations, invest in reliability and trust for healthcare operations, and scale its team. Founded by Sriram Somasundaram and Rishabh Jain and headquartered in San Francisco, Latent has raised $80M in total funding from investors including Transformation Capital, Spark Capital, McKesson Ventures, Conviction, General Catalyst, and Y Combinator.

Participated · Series D · Feb 2026

Headquartered in Palo Alto, Midi Health operates a nationwide virtual clinic that addresses gaps in women’s healthcare from perimenopause and menopause to broader chronic and preventive needs. The company’s proprietary AI engine analyzes patient charts to personalize diagnosis, streamline scheduling and documentation, and continuously refine clinical protocols using one of the industry’s largest women’s-health datasets. Midi currently has insurance contracts that give more than 45 million U.S. women in-network access to its services, and over 25,000 patients seek care on the platform each week. Outcomes data show a 28-percentage-point increase in breast-cancer screening adherence, an 11-point rise in colorectal screening adherence, and up to a 13 percent reduction in total cost of care, alongside clinically significant reductions in A1c and LDL levels. The business complements its clinical model with an expanding specialist roster covering OB-GYN, cardiology, endocrinology, mood disorders, dermatology, longevity, and more. Recent executive hires from Tesla, Google, Meta, Lyft, and Omada Health signal a push to scale operations and brand awareness. Following its latest financing, Midi is valued at more than $1 billion and plans to broaden its AI capabilities and extend comprehensive women’s care across every life stage.

Led · Series A · Jan 2026

Prudentia Sciences provides an artificial-intelligence platform that enables pharmaceutical companies, biotechs, and financial institutions to evaluate breakthrough medicines with greater speed and rigor. The system synthesizes complex clinical signals into actionable insights and uses a human-in-the-loop workflow to facilitate secure, compliant collaboration among buyers, sellers, and intermediaries. Operating as a single, continuously updated source of truth, the platform helps teams make high-stakes acquisition, licensing, and investment decisions more confidently and in a fraction of the traditional time. Its explainable AI and intelligent automation modernize a traditionally fragmented diligence process. With fresh capital in hand, the company plans to expand product capabilities, deepen both technical and non-technical intelligence, and scale commercial operations. Geographic expansion to the Asia-Pacific and Europe is also on the roadmap. Headquartered in Cambridge, Massachusetts, Prudentia has raised $27 million to date, including a $7 million seed round completed in 2024.

Participated · Series A · Oct 2025

Oath Surgical, headquartered in San Francisco, CA, has developed OathOS, an AI-powered operating-room platform that embeds automation across pre-, intra- and post-operative workflows. The system delivers real-time data and streamlined processes for surgeons, promises faster, same-day recovery for patients, and offers payors a lower-cost, transparent care model. The company is building a unified, national network of surgeon-owned, tech-enabled surgery centers connected by this common software backbone, aligning incentives for all stakeholders. Founded by CEO Oliver Keown, Oath Surgical aims to channel complex procedures into value-based, lower-cost settings while allowing surgeons to retain autonomy. With its latest capital infusion, the company plans to expand into new specialties such as oncology, scale its nationwide network of centers, and further advance the OathOS platform. Although detailed revenue or user metrics were not disclosed, the firm’s recent $24 million Series A financing underscores investor confidence in its model and growth prospects.